Trial · NCT07896629
Temporal Interference Stimulation for Upper-Limb Motor Recovery in Early Subacute Stroke
NCT07896629, Not applicable, Not yet recruiting, Xuanwu Hospital, Beijing
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Temporal Interference Stimulation for Upper-Limb Motor Recovery in Early Subacute Stroke. Trials, record NCT07896629. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07896629
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Temporal Interference Stimulation for Upper-Limb Motor Recovery in Early Subacute Stroke
- NCT number
- NCT07896629
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 60 participants, estimated
- Lead sponsor
- Xuanwu Hospital, Beijing
- Conditions
- Acute Ischemic Stroke
- Interventions
- Transcranial Temporal Interference Stimulation (tTIs), Sham Transcranial Temporal Interference Stimulation (Sham tTIs)
- First posted
- 2026-10-27
- Last updated
- 2026-11-06
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Fugl-Meyer Assessment of Upper Extremity (FMA-UE) | 20 days after the start of intervention | Change in Fugl-Meyer Assessment of Upper Extremity score, range 0-66; higher score indicates better upper limb motor function. |
| Secondary | Action Research Arm Test (ARAT) | 20 days after the start of intervention | The Action Research Arm Test scale is used to assess upper limb activity and functional ability. Total possible scores range from 0 to 57. Higher scores indicate better upper limb functional performance. |
| Secondary | Global disability: Modified Rankin Scale (mRS) | 20 days after the start of intervention | The Modified Rankin Scale is an ordinal scale used to assess functional disability and dependence in activities of daily living after stroke. Scores range from 0 to 6. Higher scores indicate worse functional outcome, with a score of 6 representing death. |
| Secondary | National Institutes of Health Stroke Scale (NIHSS) | 20 days after the start of intervention | The National Institutes of Health Stroke Scale is used to quantify neurological deficit after stroke. Total possible scores range from 0 to 42. Higher scores indicate more severe neurological impairment (worse outcome). |
| Secondary | Multimodal magnetic resonance imaging (MRI) | Assessments were performed at 1 and 20 days after the initiation of the intervention | Multimodal MRI, including functional MRI (fMRI), diffusion tensor imaging (DTI), and three-dimensional T1-weighted imaging, is acquired to assess structural-functional coupling of the dentato-thalamo-cortical (DTC) pathway. Structural-functional connectivity (SFC) is calculated as the coupling index between DTI-derived structural connectivity and resting-state fMRI functional connectivity along the DTC pathway. Higher SFC values indicate stronger structural-functional coupling of this pathway. |
| Secondary | Electroencephalography (EEG) | Assessments were performed at 1 and 20 days after the initiation of the intervention | EEG is recorded synchronously during temporal interference (TI) stimulation. Inter-trial phase coherence (ITPC) is computed to quantify the consistency of phase-locked cortical responses across trials, ranging from 0 to 1. Higher ITPC indicates more reliable phase-locked cortical activation. |
| Secondary | Transcranial Magnetic Stimulation (TMS)-Induced Motor Evoked Potentials (MEP) | Assessments were performed at 1 and 20 days after the initiation of the intervention | Single-pulse transcranial magnetic stimulation (TMS) is delivered over the primary motor cortex. Surface electromyography records motor evoked potentials from the target muscle. Peak-to-peak MEP amplitude is measured in microvolts (μV). Larger amplitude indicates higher corticospinal excitability. |
| Other | adverse events | 20 days after the start of intervention | The incidence and severity of adverse events, including adverse events related to the intervention, assessed throughout the intervention period. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers9
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07896629
GET https://conductscience.org/api/trials/v1/NCT07896629/registered